Enanta Pharmaceuticals Stock Today
| ENTA Stock | USD 6.31 0.13 2.02% |
PerformanceWeak
| Odds Of DistressBelow Average
|
Enanta Pharmaceuticals is trading at 6.31 as of the 23rd of March 2025, a 2.02 percent decrease since the beginning of the trading day. The stock's open price was 6.44. Enanta Pharmaceuticals has 45 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of March 2013 | Category Healthcare | Classification Health Care |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts. The company has 21.33 M outstanding shares of which 3.57 M shares are currently shorted by private and institutional investors with about 5.11 trading days to cover. More on Enanta Pharmaceuticals
Moving against Enanta Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Enanta Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and President and Director | Jay Luly | ||||
| Thematic Idea | Trump Equities (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Trump Equities, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsEnanta Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Enanta Pharmaceuticals' financial leverage. It provides some insight into what part of Enanta Pharmaceuticals' total assets is financed by creditors.
| |||||
Enanta Pharmaceuticals (ENTA) is traded on NASDAQ Exchange in USA. It is located in 4 Kingsbury Avenue, Watertown, MA, United States, 02472 and employs 131 people. Enanta Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 134.61 M. Enanta Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 21.33 M outstanding shares of which 3.57 M shares are currently shorted by private and institutional investors with about 5.11 trading days to cover.
Enanta Pharmaceuticals currently holds about 253.29 M in cash with (78.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Enanta Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationEnanta Pharmaceuticals holds a total of 21.33 Million outstanding shares. The majority of Enanta Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Enanta Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Enanta Pharmaceuticals. Please pay attention to any change in the institutional holdings of Enanta Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that almost five hundred sixty-nine thousand five hundred seventy-eight invesors are currently shorting Enanta Pharmaceuticals expressing very little confidence in its future performance.
Check Enanta Ownership Details
Enanta Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| D. E. Shaw & Co Lp | 2024-12-31 | 421.6 K | |
| Northern Trust Corp | 2024-12-31 | 387.4 K | |
| Stonepine Capital Management Llc | 2024-12-31 | 331.9 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 297.1 K | |
| Jacobs Levy Equity Management, Inc. | 2024-12-31 | 290 K | |
| Assenagon Asset Management Sa | 2024-12-31 | 192.9 K | |
| Caligan Partners Lp | 2024-12-31 | 184.8 K | |
| Sio Capital Management, Llc | 2024-12-31 | 177 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 163.1 K | |
| Krensavage Asset Management, Llc | 2024-12-31 | 2.1 M | |
| Farallon Capital Management, L.l.c. | 2024-12-31 | 2.1 M |
Enanta Pharmaceuticals Historical Income Statement
Enanta Stock Against Markets
Enanta Pharmaceuticals Corporate Management
| Nathaniel JD | General VP | Profile | |
| Scott MD | Senior Officer | Profile | |
| Nathalie MD | Consultant | Profile | |
| Jennifer Viera | Executive Communications | Profile | |
| Tara Kieffer | Senior Development | Profile | |
| Brendan Luu | Senior Development | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (4.95) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.